Pleased you saved yourself $10,000 and did a bit of research.
Now maybe you accept we are both on the same side here. We both have less shares than we started with (after 19th), but we both have shares in a company with tranformational biotech IP that should increase in value steadily as the consolidation of shareholding completes and the application of the technology unfolds.
Better to have less shares in the market anyway, as the value should increase proportionately, and the company starts to be percieved as a"real" commercial entity and not just a shell, as it was before.